A GLAZED-TILE READING PANEL · A TWO-PEPTIDE BLEND
BPC-157 TB-500 is a two-peptide research blend studied for tendon, wound, and angiogenesis repair — read here from the record.
Two peptides, one panel: BPC-157 supplies the cytoprotective, pro-angiogenic signal; TB-500 supplies the cell-migration signal. Every finding is single-compound, mostly rodent, and cited to its study.
What the Wolverine blend sets side by side
BPC-157 TB-500 is the research-community name for a two-peptide tissue-repair pairing marketed as "Wolverine." It is not a single chemical entity and not an approved product. It pairs BPC-157 — Body Protection Compound 157, a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419 Da) derived from a human gastric-juice protein — with TB-500, the synthetic N-acetylated heptapeptide Ac-LKKTETQ (~889 Da) corresponding to residues 17-23 of Thymosin Beta-4 [1][3].
The two peptides do different jobs. BPC-157 acts as a local cytoprotective and pro-angiogenic signal: it up-regulates VEGFR2 with downstream Akt-eNOS activation and accelerated blood-flow recovery in ischemic rat muscle [2]. TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it by capping both ends, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization [3]. The blend's appeal is that these are complementary, largely non-overlapping pathways. The honest caveat sits right beside it: no controlled study has tested the two together, and a 2025 systematic review of BPC-157 in orthopaedic sports medicine — 36 studies, only one in humans — found "no clinical safety data" and makes no mention of TB-500 or any combination [9].
This site is a reading panel, not a clinic and not a vendor. It sets each finding and each constituent in its own tile, marks which leg of the blend an evidence point belongs to, and lays the Wolverine legal status and 503A access record out in the open rather than burying it.
BPC 157 TB 500: What the Wolverine Blend Pairs
BPC 157 TB 500 — the unpunctuated form of the same pairing — pairs two peptides with two distinct, independently characterized mechanisms. BPC-157 is the cytoprotective, pro-angiogenic leg; TB-500 is the cytoskeletal, cell-migration leg. The pairing is read as "two complementary modules, one repair panel," which is the rationale behind the "synergy" claim.
That synergy is a theoretical extrapolation, not a measured result. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together. The structural and signaling facts for each peptide are well attested individually [2][3]; the combined effect is an inference from those separate mechanisms. The BPC-157 and TB-500 mechanisms page sets the two legs out in full, side by side.
What the BPC-157 TB-500 Stack Is
The BPC-157 TB-500 stack is a two-peptide tissue-repair pairing, not an approved medicine. Commercial "Wolverine" vials are commonly labeled with a combined per-vial mass — for example ~10 mg BPC-157 + ~10 mg TB-500 — but no standardized composition or ratio is clinically validated, and the actual BPC-157:TB-500 ratio in unregulated material is not guaranteed [1].
A second identity caveat compounds the first. "TB-500" as sold is the Ac-LKKTETQ heptapeptide (~889 Da), but the overwhelming majority of efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4963 Da) [4][8]. The blend inherits that gap for one of its two components. Read the research dose ranges and the honest limits before treating any vendor protocol as validated.
What the record contains, and what it does not
Read plainly, the BPC-157 TB-500 evidence sorts into two stacks. The first is genuinely strong, and it is single-compound and preclinical: BPC-157 restored load-to-failure in fully transected rat Achilles tendon at 10 microg/kg [1] and improved blood-flow recovery in ischemic rat muscle through a VEGFR2-Akt-eNOS angiogenic signal [2]; Thymosin Beta-4 raised re-epithelialization 42% at 4 days and up to 61% at 7 days in a rat wound model [5] and has a 2-angstrom crystal structure for its 1:1 G-actin sequestration [3]. Those are not marketing claims. They are measured results with citations.
The second stack is what is missing, and it is the part a "legit" reading has to keep in view. There is no controlled trial of the combination, no defined synergy ratio or endpoint, and a 2025 systematic review of BPC-157 — 36 studies, one human — recorded "no clinical safety data" and did not mention TB-500 [9]. Human data exist only for the individual peptides and are thin, and the human "TB-500" data are actually for the full-length parent protein [4][8]. This site keeps both stacks visible: the BPC-157 and TB-500 mechanisms and the BPC-157 TB-500 wound healing research on one side, the gaps and the Wolverine legal status and 503A access record on the other.